Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...

and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Eli Lilly and Company (NYSE:LLY – Get Free Report) had its target price lowered by equities researchers at Citigroup from ...

Eli Lilly and Company (NYSE:LLY – Free Report) had its price target reduced by Wells Fargo & Company from $1,000.00 to ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

supporting products like GLP-1 agonist Trulicity (dulaglutide) and dual GIP/GLP-1 agonist Mounjaro (tirzepatide) for diabetes, as well as newly-approved obesity therapy Zepbound (tirzepatide).